Isracann Biosciences Inc. ISCNF
OTC PK
| 08/31/2022 | 05/31/2022 | 02/28/2022 | 11/30/2021 | 08/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -50.27% | -- | -- | -- | -- |
| Depreciation & Amortization | -0.91% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.81% | -- | -- | -- | -- |
| Operating Income | 49.81% | -- | -- | -- | -- |
| Income Before Tax | 82.42% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 82.44% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 82.44% | -- | -- | -- | -- |
| EBIT | 49.81% | -- | -- | -- | -- |
| EBITDA | 50.27% | -- | -- | -- | -- |
| EPS Basic | 83.19% | -- | -- | -- | -- |
| Normalized Basic EPS | 54.22% | -- | -- | -- | -- |
| EPS Diluted | 83.19% | -- | -- | -- | -- |
| Normalized Diluted EPS | 54.22% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 7.19% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 7.19% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |